Adenovirus-Vectored Johnson & Johnson SARS-CoV-2 Vaccine: Reassuring Initial Results

Abstract

Thus far, two SARS-CoV-2 mRNA vaccines have received Emergency Use Authorization, and two adenovirus-vectored vaccines are in phase 3 studies. In an